EP Patent

EP2502621A1 — Crystalline forms of bupropion HBr

Assigned to Valeant International Bermuda · Expires 2012-09-26 · 14y expired

What this patent protects

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to t…

USPTO Abstract

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Drugs covered by this patent

Patent Metadata

Patent number
EP2502621A1
Jurisdiction
EP
Classification
—
Expires
2012-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Valeant International Bermuda
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.